Stock-Based Compensation (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
| Share-Based Payment Arrangement [Abstract] |
|
| Summary of RSU and RSA Activity |
The following table summarizes the RSU and RSA activity for the nine months ended September 30, 2024: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Service- based RSUs | | RSAs | | | | Market and Performance- based RSUs | | Total RSUs and RSAs | | Weighted- average grant date fair value | | Unvested as of December 31, 2023 | 25,406,057 | | | 87,030 | | | | | 1,393,446 | | | 26,886,533 | | | $ | 29.17 | | | Granted | 4,815,577 | | | 153,648 | | | | | 43,353 | | | 5,012,578 | | | $ | 49.80 | | Vested | (15,381,261) | | | (43,516) | | | | | (1,351,867) | | | (16,776,644) | | | $ | 29.41 | | Canceled/Forfeited | (1,262,437) | | | — | | | | | (30,789) | | | (1,293,226) | | | $ | 29.92 | | | Unvested as of September 30, 2024 | 13,577,936 | | | 197,162 | | | | | 54,143 | | | 13,829,241 | | | $ | 36.29 | |
|
| Summary of Stock Option Activity |
The following table summarizes the stock option activity during the nine months ended September 30, 2024: | | | | | | | | | | | | | | | | | | | | | | | | | Outstanding stock options | | Weighted- average exercise price | | Weighted- average remaining contractual life (years) | | Aggregate intrinsic value | | (in thousands, except share, per share, and year data) | | Balance as of December 31, 2023 | 29,795,909 | | | $ | 17.83 | | | 6.00 | | $ | 500,472 | | | | | | | | | | Exercised | (11,047,254) | | | 5.70 | | | | | | Canceled/Forfeited | (89,715) | | | 8.87 | | | | | | | Balance as of September 30, 2024 | 18,658,940 | | | $ | 25.06 | | | 6.17 | | $ | 798,086 | | | Vested as of September 30, 2024 | 10,950,664 | | | $ | 11.31 | | | 4.04 | | $ | 603 | | | Vested and expected to vest as of September 30, 2024 | 18,658,940 | | | $ | 25.06 | | | 6.17 | | $ | 798,086 | |
|
| Summary of Components of Stock-Based Compensation Expense |
The following table summarizes the components of stock-based compensation expense recognized in the consolidated statements of operations for all periods presented: | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | | 2024 | | 2023 | | 2024 | | 2023 | | (in thousands) | | Cost of revenue | $ | 70 | | | $ | 19 | | | $ | 389 | | | $ | 82 | | | Research and development | 41,343 | | | 5,157 | | | 387,801 | | | 18,407 | | | Sales and marketing | 7,451 | | | 1,249 | | | 75,116 | | | 4,335 | | | General and administrative | 25,894 | | | 2,967 | | | 253,226 | | | 9,151 | | Stock-based compensation expense | $ | 74,758 | | | $ | 9,392 | | | $ | 716,532 | | | $ | 31,975 | |
|